Prognostic Significance of Periacinar Retraction Clefting in Prostatic Adenocarcinoma
Virgilia Macias, Andre Kajdacsy-Balla. University of Illinois at Chicago, Chicago, IL
Background: Periacinar retraction clefting is one of the proposed additional supportive diagnostic criteria in prostate cancer. Some studies have shown its potential prognostic significance in several tumors. A recent report indicates that extensive retraction predicts biochemical recurrence-free survival in prostate carcinoma. This study examines the presence and extent of clefting in a nested case-control prostate cancer cohort to evaluate its predictive value.
Design: Formalin fixed, paraffin embedded tissues from prostatectomy specimens from the Cooperative Prostate Cancer Tissue Resource were analyzed (n=386). Patients with PSA recurrence (n=193) were paired 1:1 for year of surgery, race, age, Gleason grade and pathological stage with patients without recurrence (n=193). All cases were free of known metastasis at the time of surgery and had ≥5 years follow-up. Only neoplastic acini and nests with retraction in ≥50% of circumference were counted as positive for clefting. Based on the proportion of clefts within the tumor, the extent was graded as 0 (absent to rare); 1+ (1 to 25%); 2+ (26% to 50%); 3+ (51% to 75%); and 4+ (>75%). Groups were compared for differences by the paired Wilcoxon Signed-Rank Test.
Results: Overall, periacinar clefting was noted in 45.08% of the recurrence cases, and 38.34% of the non-recurrence cases; and proportions (scale 1-4) between the two groups were 36.27%, 4.14%, 2.60%, and 2.07% versus 30.57%, 3.63%, 2.07%, and 2.07%. However, no significant differences between the two groups were found by statistical analysis (p=0.28).
Conclusions: In contrast with previous reports on carcinoma of the prostate and other organs, our results do not demonstrate significant associations between the presence or the extent of clefting with outcome after subjects were matched by age, race, Gleason score and pathologic stage.
Category: Genitourinary (including renal tumors)
Monday, March 19, 2012 1:00 PM
Poster Session II # 187, Monday Afternoon